A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach
Rhythm Pharmaceuticals (RYTM) has gained attention due to the FDA's expanded approval of IMCIVREE for acquired hypothalamic obesity, leading to a 13.81% share price return in 7 days. The company is currently considered undervalued by Simply Wall St's narrative, with a fair value estimate of $137.27, although its price-to-sales ratio is significantly higher than industry averages, indicating potential valuation risk. Investors should consider the potential for growth from new indications and age groups for IMCIVREE alongside the company's operating losses and reliance on the drug.
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Rhythm Pharmaceuticals announced changes to its Board of Directors, welcoming Kim Popovits and thanking Ed Mathers for his service. Kim Popovits brings over 40 years of experience in life sciences, previously leading Genomic Health and holding senior roles at Genentech and American Critical Care. The company highlights her expertise in commercialization, reimbursement, and governance as valuable for its growth and mission in rare neuroendocrine diseases.
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares
Rhythm Pharmaceuticals' Executive Vice President and Head of International, Yann Mazabraud, converted 12,875 restricted stock units (RSUs) into common shares on April 1, 2026, at an exercise price of $0.00 per share. This transaction increased his direct holdings to 66,030 shares of common stock. The RSUs vest in annual installments between April 2024 and April 2028, and this filing did not involve any open-market sales.
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3
Rhythm Pharmaceuticals (RYTM) director Kimberly J. Popovits has filed an initial Form 3, which is a statement of beneficial ownership for insiders. The filing indicates her role as a director but does not report any stock transactions or derivative positions, meaning no insider trades are disclosed in this initial ownership statement. This document serves to establish her insider status and beneficial ownership reporting for the company.
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com
Rhythm Pharmaceuticals has appointed Kim Popovits to its board of directors, replacing Ed Mathers. Popovits brings over 40 years of experience in the life sciences sector, including leadership roles at Genomic Health and Genentech. The company, focused on rare neuroendocrine diseases, has seen its stock surge 73% in the past year and recently received positive regulatory opinions for its lead product, IMCIVREE.
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits
Rhythm Pharmaceuticals announced changes to its Board of Directors, with Kim Popovits joining as a new non-employee Class II director and Edward T. Mathers resigning. Popovits brings over 40 years of life sciences leadership, including her role as former Chairman, CEO, and President of Genomic Health. The company stated Mathers' resignation was not due to any disagreement with Rhythm's operations, policies, or practices.
Rhythm Pharmaceuticals Appoints Kim Popovits to Board
Rhythm Pharmaceuticals, Inc. announced the appointment of Kim Popovits to its Board of Directors and the departure of Ed Mathers. Popovits brings extensive leadership experience in biotechnology and diagnostics, having previously served as Chairman, CEO, and President of Genomic Health. Her expertise in commercialization and governance is expected to be valuable as Rhythm advances its mission in rare neuroendocrine diseases.
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Rhythm Pharmaceuticals announced changes to its Board of Directors, welcoming Kim Popovits and thanking Ed Mathers for his service. Popovits brings extensive leadership experience in biotechnology and commercialization, which is expected to support the company's mission and growth. Rhythm Pharmaceuticals, a biopharmaceutical company, focuses on rare neuroendocrine diseases and its lead asset, IMCIVREE® (setmelanotide), is approved for specific obesity conditions.
Rhythm Pharmaceuticals Announces Appointment of Kim Popovits as Director and Departure of Ed Mathers
Rhythm Pharmaceuticals announced the appointment of Kim Popovits to its Board of Directors and the departure of Ed Mathers. Popovits brings over 40 years of experience in life sciences, previously leading Genomic Health and holding key roles at Genentech, which is expected to support Rhythm's growth and mission. The company expressed gratitude to Mathers for his extensive contributions since 2013, while emphasizing Popovits' expertise in commercialization and governance for their ongoing efforts in rare neuroendocrine diseases.
Rhythm Pharmaceuticals adds Kim Popovits to board of directors
Rhythm Pharmaceuticals (NASDAQ:RYTM) has announced the appointment of Kim Popovits to its board of directors, replacing Ed Mathers. Popovits brings over 40 years of experience in the life sciences sector, with a background in commercialization, reimbursement, and governance. This news follows recent positive regulatory opinions for the company's lead product, IMCIVREE, and several analysts maintaining "Buy" or "Outperform" ratings for RYTM stock.
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Rhythm Pharmaceuticals (NASDAQ:RYTM) by 75.6% in the fourth quarter, selling 33,823 shares. Despite this, insiders have been net sellers in recent months, and analysts maintain a "Moderate Buy" rating with an average price target of $131.13, while the company's stock currently trades around $86.29. The company also reported beating EPS estimates for the last quarter but remains unprofitable.
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Rhythm Pharmaceuticals has announced changes to its Board of Directors, with Kim Popovits appointed as a new director and Ed Mathers departing. Popovits brings extensive leadership experience in biotechnology and commercial innovation, which is expected to be valuable for the company's mission and growth. The company also expressed gratitude to Ed Mathers for his dedicated service since 2013.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) saw a 12.6% jump in its stock price, attributed to a positive opinion from the European Medicines Agency regarding the expansion of Imcivree's marketing authorization. Despite this rally, the company faces a 2% lower consensus EPS estimate for the upcoming quarter, raising questions about sustained strength. The stock currently holds a Zacks Rank #3 (Hold).
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide
Rhythm Pharmaceuticals (RYTM) announced positive topline results from its Phase 3 EMANATE trial, showing that its drug setmelanotide met all primary and secondary endpoints for treating severe obesity and hyperphagia in individuals with six specific genetic diseases. The study demonstrated significant weight loss and reduction in hunger scores across various patient populations. This success supports the potential for setmelanotide to address rare genetic causes of obesity.
Rhythm Pharma higher after FDA label expansion for lead drug
Rhythm Pharmaceuticals' shares rose after the FDA approved a label expansion for its drug, IMCIVREE, to include patients with Bardet-Biedl syndrome. This approval gives IMCIVREE the broadest label among pro-opiomelanocortin pathway drugs. The company is now poised to market the drug to an additional patient population.
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025 - News and Statistics
Rhythm Pharmaceuticals, a smaller player in the anti-obesity market, saw its revenue reach $189.8 million in 2025, a 46% increase. Imcivree, its sole commercial product, recently received FDA approval for acquired hypothalamic obesity, adding 10,000 potential patients. However, the company faces challenges, including a limited patient population and a recent phase 3 trial failure for another indication that would have targeted an additional 29,000 patients.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) saw its shares jump 12.6% recently, following a positive opinion from the European Medicines Agency for its drug Imcivree, expanding its potential use for hypothalamic obesity. Despite this surge, the company faces a recent 2% downward revision in its quarterly EPS estimate, suggesting potential challenges ahead. Investors should monitor RYTM closely to see if the recent stock momentum can be sustained despite the negative earnings estimate trend.
Discipline and Rules-Based Execution in RYTM Response
This article provides an AI-driven analysis of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), indicating weak near and mid-term sentiment despite a positive long-term outlook. It details various trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis highlights an elevated downside risk due to the absence of additional long-term support signals.
Rhythm Pharmaceuticals’ Stock Jumps After New Drug Approval
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) saw its stock jump over 10% following the FDA's expanded approval of its obesity treatment, Imcivree, for patients aged four and above with acquired hypothalamic obesity. This regulatory success has bolstered investor confidence, positioning the company for significant growth and diversification despite some financial challenges. Analysts maintain a positive outlook, anticipating further market expansion, particularly with strategic moves into Europe.
RYTM PE Ratio & Valuation, Is RYTM Overvalued
This article analyzes Rhythm Pharmaceuticals Inc (RYTM)'s valuation metrics, including its P/B ratio, FCF yield, and P/S ratio, to determine if the stock is overvalued. It concludes that RYTM is currently in the "Fair zone" with a forward P/S ratio of 27.10, relative to a five-year average of -12.69. The fair price range is estimated between $8.32 and $133.60, based on relative valuation methods, and its P/S ratio is noted to be significantly above the industry average but potentially sustainable due to robust revenue growth.
Jefferies Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $125
Jefferies has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target of $125. This indicates a continued positive outlook from the firm regarding the company's stock performance.
FDA’s Approval Sparks Optimism for Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) saw its stock price surge by over 10% following the FDA's approval of Imcivree's expanded indication for treating acquired hypothalamic obesity. Major financial institutions like Citi and BofA have raised their price targets for Rhythm, citing this approval as a significant growth catalyst and reinforcing the company's leadership in rare obesity treatments. This expanded commercial scope and investor optimism suggest a promising future trajectory for the company despite some financial hurdles.
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide
Rhythm Pharmaceuticals (RYTM) announced positive topline results from the Phase 3 EMANATE trial of setmelanotide in patients with Bardet-Biedl Syndrome (BBS). The trial met its primary and all key secondary endpoints, demonstrating statistically significant reductions in hyperphagia and body mass index (BMI) compared to placebo. These results are expected to support regulatory submissions for broader label expansion.
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity
Rhythm Pharmaceuticals experienced a 13.3% stock drop despite the European Medicines Agency's positive opinion to expand IMCIVREE's label for acquired hypothalamic obesity, mirroring a recent U.S. approval. This expansion into a broader patient population is critical for Rhythm, as the company heavily relies on this single drug to offset ongoing losses and high R&D costs. Despite the regulatory success, the stock's decline highlights investor concerns about operating losses and potential future equity dilution.
-7.42% for Rhythm Pharmaceuticals stock as sellers dominate near key support
Rhythm Pharmaceuticals (RYTM) stock dropped 7.42% today, continuing a bearish trend despite the recent approval of its therapy for acquired hypothalamic obesity. The stock is trading below major moving averages, indicating strong selling pressure across all timeframes. Technical indicators suggest oversold conditions, which might limit immediate further downside, but a continued decline is more likely given the current market setup.
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105
H.C. Wainwright has reaffirmed its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its target price of $105. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.
Vanguard disaggregates holdings; reports 0 shares in Rhythm Pharmaceuticals (NASDAQ: RYTM)
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares (0%) of Rhythm Pharmaceuticals Inc. common stock. This change is due to an internal realignment where certain Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing clarifies that this is an administrative reassignment of reporting responsibility, not an economic divestiture or sale of shares.
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for
Rhythm Pharmaceuticals announced that the European Medicines Agency's CHMP has issued a positive opinion to expand the marketing authorization for IMCIVREE (setmelanotide). This expansion would include the treatment of obesity and control of hunger in adults and children aged 4 and above with acquired hypothalamic obesity (HO). The decision, which follows closely on a recent FDA approval, addresses a significant unmet medical need and targets the root cause of this rare neuroendocrine disease.
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports Material Event
Rhythm Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to expand the marketing authorization for IMCIVREE (setmelanotide). This expansion recommends including the treatment of obesity and control of hunger in adults and children aged 4 and above with acquired hypothalamic obesity due to hypothalamic injury or impairment. The European Commission is expected to make a final decision in the second quarter of 2026, which could address a significant unmet medical need in this patient population.
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals announced that the European Medicines Agency's (EMA) CHMP issued a positive opinion supporting the expansion of IMCIVREE® (setmelanotide) for treating obesity and hunger control in patients with acquired hypothalamic obesity (HO) aged 4 and above. This decision comes shortly after the FDA's approval for the same indication. The European Commission is expected to make a final decision in Q2 2026, targeting a significant unmet medical need for patients with this rare neuroendocrine disease.
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130
TD Cowen has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained a target price of $130. This indicates a continued positive outlook from the analyst firm on the company's stock performance.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication
Rhythm Pharmaceuticals (RYTM) received expanded FDA approval for IMCIVREE to treat hypothalamic obesity, yet its short-term share price has declined despite long-term gains. The company is currently valued at $6.0 billion, with a significant discount to the average analyst price target of $131.50, suggesting it may be undervalued. However, its high P/S ratio of 31.5x, compared to peers at 6.8x, indicates investors are already paying a premium for its growth story, highlighting both opportunity and risk.
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide
Rhythm Pharmaceuticals' EMANATE Phase 3 trial for setmelanotide in four genetic cohorts missed its primary endpoint of BMI change at 52 weeks. Despite this, post-hoc analyses showed signals of activity in POMC heterozygous and SRC1 populations, with management emphasizing challenges in patient selection and high discontinuation rates. The company will now focus on next-generation therapies and refine genetic testing for hypothalamic obesity, Prader-Willi, and Bardet-Biedl studies.
Rhythm Pharmaceuticals wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% placebo‑adjusted BMI
Rhythm Pharmaceuticals (RYTM) received FDA approval for its drug IMCIVREE to treat acquired hypothalamic obesity in adults and children aged 4 and older. This approval was based on a pivotal Phase 3 study (TRANSCEND) which demonstrated an 18.4% placebo-adjusted BMI reduction. IMCIVREE will be immediately available in the U.S., supported by the Rhythm InTune patient program.
Rhythm Pharmaceuticals (Nasdaq: RYTM) gains FDA OK for IMCIVREE in acquired hypothalamic obesity
Rhythm Pharmaceuticals (Nasdaq: RYTM) has received FDA approval for an expanded indication of IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity (HO) in adults and children aged 4 and older. This makes IMCIVREE the first and only FDA-approved therapy for this rare condition, which affects an estimated 10,000 people in the U.S. The approval is supported by positive Phase 3 trial results showing a significant reduction in BMI.
Rare obesity treatment for hypothalamic injury patients gets one U.S. pharmacy
PANTHERx Rare has been selected by Rhythm Pharmaceuticals Inc. as the exclusive U.S. specialty pharmacy for the expanded indication of IMCIVREE (setmelanotide) for adults and children aged 4 and older with acquired hypothalamic obesity. This partnership will leverage PANTHERx's RxARECARE model to provide individualized support, education, and financial/insurance navigation for patients. The collaboration extends PANTHERx's existing role as the exclusive IMCIVREE pharmacy for certain genetic obesity indications since 2020.
Rhythm Pharmaceuticals jumps as investors focus on FDA decision timing for hypothalamic obesity label expansion
Rhythm Pharmaceuticals (RYTM) saw its stock jump 3.2% due to investor anticipation surrounding the FDA's PDUFA goal date of March 20, 2026, for IMCIVREE's label expansion in acquired hypothalamic obesity. The company's recent Phase 3 data and regulatory timeline updates have heightened event-driven trading. Insider selling has been noted, while institutional investors show mixed activity, and analysts are predominantly bullish with a median price target of $139.5.
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide
Rhythm Pharmaceuticals announced topline results from its Phase 3 EMANATE trial for setmelanotide, which did not meet its primary endpoints for reducing BMI. However, post hoc analysis showed significant BMI reductions in specific patient groups with rare genetic obesity, indicating potential for targeted treatment. The company plans to use this data to refine its approach for neuroendocrine diseases and develop next-generation MC4R agonists, while noting the drug's safety profile remained consistent.
Why Is Rhythm Pharma Stock Gaining Friday? - Rhythm Pharmaceuticals (NASDAQ:RYTM)
Rhythm Pharmaceuticals (RYTM) saw its stock rise after the FDA approved an expanded indication for its drug Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). This approval makes Imcivree the first and only FDA-approved therapy for acquired HO, a rare disease characterized by significant weight gain. The approval was supported by positive results from the Phase 3 TRANSCEND trial, which showed a statistically significant reduction in BMI among patients treated with setmelanotide.
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Rhythm Pharmaceuticals (RYTM) saw its stock initially surge but then fall after the FDA approved its obesity drug, Imcivree, for patients with acquired hypothalamic obesity. This new approval expands Imcivree's market beyond its existing use for genetically driven forms of obesity, distinguishing it from GLP-1 drugs by Eli Lilly and Novo Nordisk. The article highlights that Rhythm's drug is targeting a specific patient population where broader obesity treatments may not be effective.
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
Rhythm Pharmaceuticals announced that its Phase 3 EMANATE trial for setmelanotide did not meet its primary endpoints across four substudies targeting genetically-driven MC4R pathway obesities. Despite the setback, the company highlighted encouraging signals from additional analyses of the POMC/PCSK1 and SRC1 substudies, which they believe will inform the development of next-generation MC4R agonists. Rhythm Pharmaceuticals remains committed to advancing targeted therapies for patients with rare genetic obesities, noting the significant unmet medical need in this population.
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE®
Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 and older. This marks the first and only FDA-approved therapy for acquired HO, a rare disease causing severe weight gain due to hypothalamic injury. The approval is supported by the Phase 3 TRANSCEND trial, which showed a significant -18.4% placebo-adjusted BMI reduction.
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE®
Rhythm Pharmaceuticals announced that the FDA has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients aged 4 years and older with acquired hypothalamic obesity (HO). This makes IMCIVREE the first and only FDA-approved therapy for this rare disease, which is characterized by accelerated and sustained weight gain due to hypothalamic injury. The approval is supported by positive data from the Phase 3 TRANSCEND trial, showing a significant reduction in BMI.
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced FDA approval of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older. The approval is based on the Phase 3 TRANSCEND trial, which demonstrated a significant -18.4% placebo-adjusted BMI reduction. IMCIVREE is immediately available in the U.S. and is the first and only FDA-approved therapy for this rare condition, which affects an estimated 10,000 people in the U.S.
Rhythm Awaits FDA Decision On Expanded Use Of Imcivree In Hypothalamic Obesity
Rhythm Pharmaceuticals (RYTM) is awaiting an FDA decision tomorrow, March 20, 2026, regarding its sNDA to expand the label of Imcivree for treating acquired hypothalamic obesity. Imcivree, also known as setmelanotide, is already approved for chronic weight management in adults and children aged two and older with specific rare genetic forms of obesity, including Bardet-Biedl syndrome, POMC, PCSK1, or LEPR deficiency. The article indicates that further details are available to premium subscribers.
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism
Wells Fargo increased its price target for Rhythm Pharmaceuticals (RYTM) to $143 from $136, maintaining an Overweight rating due to optimism surrounding the IMCIVREE launch for hypothalamic obesity. This decision was influenced by slightly higher revenue projections and positive feedback from physicians. Additionally, new 52-week data from the Phase 3 TRANSCEND trial for setmelanotide showed significant BMI reduction and decreased hunger scores in patients with acquired hypothalamic obesity, reinforcing the therapy's potential.
HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price
HC Wainwright has lowered its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) from $110 to $100, though it maintained a "buy" rating, indicating a potential 14% upside. This comes after Rhythm's late-stage EMANATE trial missed primary endpoints, impacting near-term label expansion, despite the company reporting a Q4 revenue beat of $57.25 million. Other analysts have also trimmed price targets while largely retaining bullish ratings, and insider selling has been noted alongside institutional investor activity.
HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica
HC Wainwright & Co. has maintained a "Buy" rating for Rhythm Pharmaceuticals (RYTM) but lowered its price target from $110.00 to $100.00. This follows a trend of several other investment firms, including Needham, Morgan Stanley, B of A Securities, Citizens, and RBC Capital, also reducing their price targets for RYTM. Despite these adjustments, the average target price from 16 analysts suggests an upside of 53.18% from the current price, with an "Outperform" consensus recommendation.
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK)
Analysts have provided insights on two healthcare companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK). Rhythm Pharmaceuticals received a maintained Buy rating from Stifel Nicolaus with a $131.00 price target, and a Strong Buy consensus from analysts. Merck & Company was maintained at a Hold rating by Bernstein with a $100.00 price target, while the overall consensus is a Moderate Buy.
Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss
Following a Phase III miss, attention is now turning to Rhythm Pharmaceuticals' drug, Imcivree, and its potential for treating hypothalamic obesity. The company, Rhythm Pharmaceuticals, is highlighted for its ongoing developments. This article also references past news about Rhythm receiving a US decision date for its hypothalamic obesity treatment and its previous Phase III success with setmelanotide.
